Plain-English translation of NCT07213934 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a combination of two treatments for people with recurrent head and neck cancer—cancer that has returned after previous radiation therapy. Participants will receive either standard radiation or proton radiation (a newer, more targeted type) followed by a medication called , which is a type of immunotherapy that helps your immune system fight cancer. The study is trying to find the safest and most effective dose of radiation to use before surgery, and then determine if adding the medication afterward helps more patients achieve a major response to treatment.
Head and neck cancer that comes back after previous radiation therapy is very difficult to treat, and outcomes are often poor with current standard approaches. Researchers believe that combining radiation therapy with this immunotherapy medication might help the body's immune system better recognize and attack cancer cells, potentially improving survival and quality of life for these patients.
You likely qualify if…
You likely don't qualify if…
The trial has two phases. In Phase I, small groups of patients will receive 3 sessions of radiation therapy before surgery, with careful monitoring to ensure safety. Based on Phase I results, Phase II will enroll about 40 patients who will be randomly assigned to receive either standard radiation or proton radiation, followed by immunotherapy treatment. Participants will have multiple visits for radiation, surgery, follow-up scans, and blood tests to monitor how well the treatment is working and watch for side effects.
AI-generated summary from trial data · Jul 8, 2026 · Not medical advice
United States